Amgen's Uplizna Hits Phase 3 Endpoints in IgG4-RD
By Colin Kellaher
Amgen on Wednesday said a late-stage study of its autoimmune drug Uplizna hit its key goals in the treatment of immunoglobulin G4-related disease, a chronic, immune-mediated disease known as IgG4-RD.
Amgen said the Phase 3 study met its primary endpoint, showing a statistically significant 87% reduction in the risk of IgG4-RD flare compared to placebo, as well as key secondary endpoints.
The Thousand Oaks, Calif., biotechnology company said it plans to seek U.S. Food and Drug Administration approval of Uplizna in IgG4-RD, followed by other key markets.
Uplizna is currently approved in the U.S., Europe and several other countries for the rare autoimmune disease neuromyelitis optica spectrum disorder.
Amgen acquired Uplizna as part of its $27.8 billion acquisition of Horizon Therapeutics last year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 05, 2024 09:43 ET (13:43 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations